Agenus | AGEN - Equity Capital And Reserves


Agenus reported $-271.11M in Equity Capital and Reserves for its fiscal quarter ending in December of 2025.





Equity Capital And Reserves Change Date
AbbVie USD -3.27B 628M Dec/2025
Agenus USD -271.11M 3.03M Dec/2025
Amgen USD 8.66B 961M Dec/2025
AstraZeneca USD 48.67B 2.78B Dec/2025
Bristol-Myers Squibb USD 18.55B 1.06B Sep/2025
Celldex Therapeutics USD 527.16M 71.2M Dec/2025
CSL USD 18.66B 2.75B Dec/2025
Eli Lilly USD 26.54B 2.74B Dec/2025
Gilead Sciences USD 22.62B 1.16B Dec/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
Glaxosmithkline GBP 22.06B 360M Dec/2025
Incyte USD 5.17B 516.28M Dec/2025
Intrexon USD 43.17M 75.33M Jun/2024
J&J USD 78.47B 0 Sep/2025
Jiangsu Hengrui CNY 61.27B 1.77B Dec/2025
Karyopharm Therapeutics USD -269.26M 30.33M Sep/2025
MacroGenics USD 55.59M 11.41M Dec/2025
Merck EUR 28.59B 344M Dec/2025
Merck USD 51.85B 2.79B Sep/2025
Northwest Biotherapeutics USD -108.65M 8.26M Sep/2025
Novartis USD 46.13B 1.38B Dec/2025
Novavax USD -127.75M 28.92M Dec/2025
Pfizer USD 92.8B 4.11B Sep/2025
Regeneron Pharmaceuticals USD 31.26B 299.1M Dec/2025
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Sangamo BioSciences USD 19.6M 14.7M Jun/2025
Veracyte USD 1.26B 36.61M Sep/2025